SEATTLE, Wash. and VANCOUVER, British Columbia, May 26, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the LD Micro Invitational Conference. The Conference is taking place in-person at the…
/Read More
SEATTLE, Wash. And VANCOUVER, British Columbia, May 13, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at the Spring Into Action Best Ideas Virtual Investor Conference. The conference is taking…
/Read More
Company to host conference call at 4:30 PM EDT today, May 12, 2022 SEATTLE, Wash and VANCOUVER, British Columbia, May 12, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2022 financial results…
/Read More
Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo Primary endpoints demonstrated 6-8x increased odds of smoking abstinence with cytisinicline compared to placebo Cytisinicline was well tolerated with single-digit rates of adverse events observed Management to host conference call today, April 27th at…
/Read More
SEATTLE, Wash and VANCOUVER, British Columbia, April 21, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its first quarter financial results and provide an update on the cytisinicline development program on Thursday,…
/Read More